ACADIA PHARMACEUTICALS INC (ACAD) research
ACADIA PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $26.41
- As of
ACADIA PHARMACEUTICALS INC (ACAD): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.
As of . Source: SEC EDGAR filings for ACAD. Method and limitations.
Share the ACAD intelligence card
See ACAD live in the terminal
Track ACAD's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ACAD terminal, freeActive signals for ACAD
- highCONSENSUS_BUY
3 tracked funds increased ACAD this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +17660% to ACAD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +212% to ACAD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8293% to ACAD (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +133% to ACAD (2026Q2)
FREE, NO ACCOUNT
Every signal on ACAD, as it fires
You are seeing 5 of 26 signals recorded on ACAD since 2026-05-16.
The five above landed across 2 days. The other 21 were recorded on 4 other days. 18 of the 26 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ACAD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 004225108 · 2026Q2 | $61.6M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 004225108 · 2026Q2 | $55.2M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 004225108 · 2026Q2 | $43M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 004225108 · 2026Q2 | $32.4M | 0.04% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 004225108 · 2026Q2 | $23.5M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 004225108 · 2026Q2 | $14.9M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 004225108 · 2026Q2 | $1.3M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACAD
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ACAD against its peers
ACAD's operating margin of 9.8% ranks in the 79th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ACAD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.1B USD | 241M USD | 91 | 16 |
| Operating margin | 9.8% | -113.0% | 79 | 16 |
| Net margin | 36.5% | -100.2% | 85 | 16 |
| Return on equity | 31.9% | -29.8% | 98 | 22 |
| P / E | 11.5x | n/a | n/a | 2 |
Peers (24): EWTX, IOVA, DFTX, MANE, TLX, ERAS, APLS, DNTH, RLAY, CRSP, TNGX, XENE, PTCT, CELC, LGND, ELVN, COGT, CPRX, TVTX, ORKA, IDYA, GRAL, CNTA, MIRM. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ACAD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ACAD signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ACADand get the insider, 13F, options, and confluence read in one view.